ChemoMetec A/S

As of June 30, 2026, ChemoMetec A/S carries a market capitalization of 839.97M, placing it among publicly traded companies globally. Its enterprise value stands at 801.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ChemoMetec A/S's next confirmed earnings release is scheduled for February 3, 2027.

As of June 30, 2026, ChemoMetec A/S has 17.30M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ChemoMetec A/S maintains a current ratio of 4.09, meaning it holds 4.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, ChemoMetec A/S's stock has declined approximately 12.05% over the past 52 weeks. The 50-day moving average sits at 70.10, while the 200-day moving average is 58.86.

As of June 30, 2026, ChemoMetec A/S holds 39.28M in cash and equivalents against 614,031.06 in total debt, resulting in a net debt position of -38.62M. Total book value stands at 97.06M, with working capital of 53.06M providing operational flexibility.